Browse > Article
http://dx.doi.org/10.7314/APJCP.2015.16.8.3241

Results of Intravesical Chemo-Hyperthermia in High-risk Non-muscle Invasive Bladder Cancer  

Ekin, Rahmi Gokhan (Department of Urology, Tepecik Teaching and Research Hospital)
Akarken, Ilker (Urology Clinic, Kemalpasa State Hospital)
Cakmak, Ozgur (Department of Urology, Tepecik Teaching and Research Hospital)
Tarhan, Huseyin (Department of Urology, Tepecik Teaching and Research Hospital)
Celik, Orcun (Department of Urology, Tepecik Teaching and Research Hospital)
Ilbey, Yusuf Ozlem (Department of Urology, Tepecik Teaching and Research Hospital)
Divrik, Rauf Taner (Department of Urology, Sifa University, Faculty of Medicine)
Zorlu, Ferruh (Department of Urology, Tepecik Teaching and Research Hospital)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.16, no.8, 2015 , pp. 3241-3245 More about this Journal
Abstract
Purpose: To examine the effectiveness of mitomycin-C and chemo-hyperthermia in combination for patients with high-risk non-muscle-invasive bladder cancer. Materials and Methods: Between November 2011-September 2013, 43 patients with high-risk non-muscle-invasive bladder cancer undergoing adjuvant chemo-hyperthermia in two centers were evaluated retrospectively. Treatment consisted of 6 weekly sessions, followed by 6 sessions. Recurrence and progression rate, recurrence-free interval and side effects were examined. Analyzed factors included age, gender, smoking status, AB0 blood group, body mass index, T stage and grade, concominant CIS assets. The associations between predictors and recurrence were assessed using multivariate Cox proportional hazard analyses. Results: A total of 40 patients completed induction therapy. Thirteen (32.5%) were diagnosed with tumor recurrence. Median follow-up was 30 months (range 9-39). Median recurrence-free survival was 23 months (range 6-36). The Kaplan-Meier-estimated recurrence-free rates for the entire group at 12 and 24 months were 82% and 61%. There was no statistically significant difference between patient subgroups. Cox hazard analyses showed that an A blood type (OR=6.23, p=0.031) was an independent predictor of recurrence-free. Adverse effects were seen in 53% of patients and these were frequently grades 1 and 2. Conclusions: Intravesical therapy with combination of mitomycin-C and chemohyperthermia seems to be appropriate in high-risk patients with non-muscle-invasive bladder cancer who cannot tolerate or have contraindications for standard BCG therapy.
Keywords
Chemohyperthermia; recurrence; mitomycin C; thermochemotherapy; non muscle-invasive bladder cancer;
Citations & Related Records
Times Cited By KSCI : 4  (Citation Analysis)
연도 인용수 순위
1 Babjuk M, Burger M, Zigeuner R, et al (2013). EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder:update 2013. Eur Urol, 64, 639-53.   DOI   ScienceOn
2 Basiri A, Shakhssalim N, Jalaly NY, et al (2014). Difference in the incidences of the most prevalent urologic cancers from 2003 to 2009 in Iran. Asian Pac J Cancer Prev, 15, 1459-63.   DOI   ScienceOn
3 Burger M, Catto JWF, Dalbagni G, et al (2013). Epidemiology and risk factors of urothelial bladder cancer. Eur Urol, 63, 234-41.   DOI   ScienceOn
4 Cheng CW, Chan SFP, Chan LW, et al (2004). 15-year experience on intravesical therapy of T1G3 urinary bladder cancer: a conservative approach. Jpn J Clin Oncol, 34, 202-5.   DOI
5 Colombo R, Lev A, Da Pozzo LF, et al (1995). A new approach using local combined microwave hyperthermia and chemotherapy in superficial transitional bladder carcinoma treatment. J Urol, 153, 959-63.   DOI
6 Colombo R, Salonia A, Leib Z, et al (2011). Long-term outcomes of a randomized controlled trial comparing thermochemotherapy with mitomycin-C alone as adjuvant treatment for non-muscle-invasive bladder cancer (NMIBC). BJU Int, 107, 912-8.   DOI
7 Divrik RT, Sahin AF, Yildirim U, et al (2010). Impact of routine second transurethral resection on the long-term outcome of patients with newly diagnosed pT1 urothelial carcinoma with respect to recurrence, progression rate, and diseasespecific survival: a prospective randomised clinical trial. Eur Urol, 58, 185-90.   DOI
8 Eser S, Zorlu F, Divtik RT, et al (2009). Incidence and epidemiological features of cancers of the genitourinary tract in Izmir between 1993-2002. Asian Pacific J Cancer Prev, 10, 491-6.
9 Grivas N, Hastazeris K, Kafarakis V, et al (2014). Efficacy of postoperative bladder irrigation with water for injection in reducing recurrence rates of non muscle invasive bladder cancer. Asian Pac J Cancer Prev, 15, 2263-6.   DOI
10 Hildebrandt B, Wust P, Ahlers O, et al (2002). The cellular and molecular basis of hyperthermia. Crit Rev Oncol Hematol, 43, 33-56.   DOI
11 Institute NC, (2010). Common terminology criteria for adverse events (CTCAE ) Version 4.0. , 2009.
12 Lammers RJM, Witjes JA, Inman B a, et al (2011). The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of non-muscle-invasive bladder cancer: a systematic review. Eur Urol, 60, 81-93.   DOI
13 Moskovitz B, Halachmi S, Moskovitz M, et al (2012). 10-year single-center experience of combined intravesical chemohyperthermia for nonmuscle invasive bladder cancer. Future Oncol, 8, 1041-9.   DOI
14 Okamura T, Akita H, Ando R, et al (2010). Intravesical bacillus Calmette-Guerin (BCG) instillation for primary and recurring T1G3 bladder cancers. Asian Pac J Cancer Prev, 11, 1107-10.
15 Okamura T, Ando R, Akita H, et al (2012). Are there time-periodrelated differences in the prophylactic effects of bacille calmette-guerin intravesical instillation therapy in Japan? Asian Pacific J Cancer Prev, 13, 4357-61.   DOI
16 Richards KA, Smith ND, and Steinberg GD, (2014). The importance of transurethral resection of bladder tumor in the management of nonmuscle invasive bladder cancer: a systematic review of novel technologies. J Urol.
17 Sangar VK, Ragavan N, Matanhelia SS, et al (2005). The economic consequences of prostate and bladder cancer in the UK. BJU Int, 95, 59-63.
18 Wang H-F, Wang J (2012). Research progress in potential urinary markers for the early detection, diagnosis and follow-up of human bladder cancer. Asian Pac J Cancer Prev, 13, 1723-6.   DOI
19 Volpe A, Racioppi M, Bongiovanni L, et al (2012). Thermochemotherapy for non-muscle-invasive bladder cancer: is there a chance to avoid early cystectomy? Urol Int, 89, 311-8.   DOI